



FORGING A NEW FRONTIER

# Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease

*This program is not affiliated with Digestive Disease Week®*

**LIVE SYMPOSIUM**

May 20, 2024 • 6:30-8:00 PM ET • Dinner: 6 PM ET

The Capital Hilton Hotel • Presidential Ballroom



# Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease



Anemia occurs frequently in patients with inflammatory bowel disease (IBD) and is one of the most commonly seen extraintestinal manifestations of disease with iron deficiency (ID) as the most common cause. Practice guidelines recommend screening all patients with IBD regularly for ID and anemia, but studies show screening is done infrequently. Additionally, patients with IBD and iron deficiency anemia (IDA) require specific considerations for the presence of active inflammation when determining whether IV or oral iron supplementation is appropriate as elevated hepcidin levels in active IBD can block oral iron absorption.

This CME Outfitters symposium entitled, *Forging a New Frontier: Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease*, will feature globally renowned faculty who will discuss screening for ID in patients with IBD, the role of hepcidin in ID pathophysiology, and the basic principles of iron metabolism and absorption, including the distinction between absolute and functional ID. The expert panel will also explore the differences between oral and intravenous (IV) iron formulations; evaluate clinical trial efficacy data on IV iron in both adult and pediatric patients; and review shared decision-making (SDM) strategies.

## Learning Objectives

**At the conclusion of this activity, learners will be able to better:**

- Incorporate comprehensive screening tests for ID in patients with IBD based on principles of ID pathophysiology and the prevalence of IDA in patients with IBD
- Evaluate the distinctions among IV iron products including current and emerging clinical trial data on efficacy, safety, and AEs such as hypersensitivity for patients with IBD
- Assess the use of IV iron in the pediatric IBD setting
- Develop patient-centered care plans with the use of SDM with patients with ID and IBD, factoring in individual patient preferences and characteristics to optimize adherence and outcomes

## Target Audience

Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), and nurses

## Financial Support

Supported by an educational grant from American Regent, Inc.

## Faculty

### Gary R. Lichtenstein, MD

Professor of Medicine

Vice Chief, Division of Gastroenterology and Hepatology, Development and Philanthropy

Emeritus Director, Program for Inflammatory Bowel Diseases  
University of Pennsylvania Health System

The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania

Hospital of the University of Pennsylvania

Gastroenterology Division, Department of Internal Medicine  
Philadelphia, PA

### Neilanjan Nandi, MD, FACP, AGAF, FACP

Associate Professor of Clinical Medicine

Division of Gastroenterology & Hepatology

The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania

Penn Presbyterian Medical Center

University of Pennsylvania

Philadelphia, PA

FORGING A NEW FRONTIER

# Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease



## Credit Information

### JOINTLY ACCREDITED PROVIDER



In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### IPCE CREDIT



This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credits for learning and change.

### PHYSICIANS (ACCME)

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSES (ANCC)

This activity is designated for 1.5 contact hours.

**California Residents:** This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC's provider number is CEP15510.

**Note to Nurse Practitioners:** The content of this CNE activity pertains to Pharmacology.

### PAS (AAPA)



CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

### ABIM MOC CREDIT



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### MIPS IMPROVEMENT ACTIVITY



Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA\_PSPA\_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

### ROYAL COLLEGE MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.



FORGING A NEW FRONTIER

# Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease



## Faculty



### Gary R. Lichtenstein, MD

Gary R. Lichtenstein, MD, is the Vice Chief, Division of Gastroenterology, Development and Philanthropy; Emeritus Director of the Inflammatory Bowel Disease Program; and Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine in New York, New York. He then completed his internship and residency in internal medicine at Duke University Medical Center in Durham, North Carolina. He also served a fellowship in gastroenterology at the Hospital of the University of Pennsylvania of the University of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease and his research has had a significant focus on the safety of current and future medical therapy. He has also focused his research on the natural history of disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn's disease.

A Fellow of the American Gastroenterological Association (AGA), the American College of Physicians, and the American College of Gastroenterology, Dr. Lichtenstein is listed in *Best Doctors in America* (inflammatory bowel disease [IBD]) and has served as Medical Secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level, including the AGA where he has served as Vice Chair of the Clinical Practice Committee and Practice Economics Committee and where he has served as Chair of the Clinical Practice Committee; the American Society for Gastrointestinal Endoscopy where he has served on the committee on training; and the American College of Gastroenterology where he has served on the Education Committee, Programs Committee, and Nominations Committee. He recently served as a member of the research committee. He has been the chair of numerous abstract review committees for IBD for the American College of Gastroenterology and the AGA and has served as section chair and moderator for numerous sessions at Digestive Disease Week. Dr. Lichtenstein is also a member of the Crohn's and Colitis Foundation of America where he served at the national level as the chair of the membership committee of the Clinical Research Alliance, on the National Grants Review Committee, on the National Physician Education Committee, and currently as chair of the Membership Committee. Additionally, he is a longstanding member of the American College of Physicians and the American Medical Association.

Dr. Lichtenstein has received numerous awards, including the National Scientific Achievement Award from the national Crohn's and Colitis Foundation of America (CCFA), for his clinical work and research. In 2020, he was recipient of the AGA's top academic clinician award (the AGA Distinguished Clinician Award in Academic Practice). He received the award for the top specialist in the University of Pennsylvania Health System (the Louis A. Duhring Award) as well as the top teaching award in all of University of Pennsylvania (the Christian R. and Mary F. Lindback Award). Additionally, he has received the medical school teaching award (the Penn Pearls Award), the Department of Medicine house staff teaching award (the Donald B. Martin Teaching Award), and the Gastroenterology Division teaching award (the Sidney Cohen Teaching Award).

Dr. Lichtenstein is listed in *Philadelphia Magazine* among top gastroenterologists for elderly in Philadelphia and among top gastroenterologists in Philadelphia (special focus: IBD). He is the recipient of the CCFA Physician of the Year Award: Philadelphia and Delaware Valley Chapters. In addition to having served on the editorial board of the journals *Gastroenterology*, *American Journal of Gastroenterology*, *Inflammatory Bowel Diseases*, *World Journal of Gastroenterology*, and *Digestive Diseases and Sciences*, Dr. Lichtenstein served as a former writer of Selected Summaries in the journal *Gastroenterology* and as the Section Editor of Selected Summaries as well as Print and Media Review in Gastroenterology for a 5-year term. He has been and is currently serving as a reviewer for journals such as *The New England Journal of Medicine*, *Gastroenterology*, *The Lancet*, *Annals of Internal Medicine*, *Clinical Gastroenterology and Hepatology*, *Gut*, *Journal of Parenteral and Enteral Nutrition*, *The American Journal of Gastroenterology*, *World Journal of Gastroenterology*, and *Journal of Clinical Gastroenterology*. He is the journal founder and Executive Editor of the PubMed-indexed journal *Gastroenterology and Hepatology*, now in press for 18 years, and has served as Associate Editor of *Therapeutic Advances in Gastroenterology*, *The Physician and Sports Medicine*, and *Clinical Investigation* and has served as Assistant Editor-in-Chief of *World Journal of Gastroenterology*. He is the author or coauthor of more than 150 primary research articles, 280 chapters, editorials, and reviews, has edited 32 books, and has presented over 350 abstracts. Dr. Lichtenstein has been an invited speaker at the local, national, and international levels, speaking at over 500 conferences, lectures, symposia, and institutional grand rounds.

# Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease



## Faculty



### Neilanjan Nandi, MD, FACP, AGAF, FRCG

Neilanjan Nandi, MD, FACP, AGAF, FRCG, is Associate Professor of Clinical Medicine at Penn Presbyterian Medical Center at the University of Pennsylvania. Dr. Nandi's practice focuses on the management of inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis) and recurrent *Clostridium difficile* (*C. difficile*) infection via fecal microbiota transplantation (FMT). Dr. Nandi serves on the executive council of the Philadelphia Crohn's & Colitis Foundation (CCF) and on the medical advisory board of the United Ostomy Associates of America (UOAA), coordinates outreach on the American College of Gastroenterology Patient Care Committee, and is a founding board member of the South Asian IBD Alliance (SAIA). He also regularly peer reviews research publications and serves on the social media editorial board for the premier journals *Inflammatory Bowel Diseases* and *Crohn's & Colitis 360*. His research has focused on studying conditions co-morbid to IBD quality of care, namely the diagnosis and management of refractory *C. difficile* infection and the application of FMT in *C. difficile*; also, characterizing the management and consequences of iron deficiency anemia and non-alcoholic fatty liver disease in patients with IBD. Dr. Nandi has authored numerous book chapters on the diagnosis and management of various viral, parasitic, mycobacterial, and bacterial infections of the gastrointestinal (GI) tract.

Dr. Nandi's fervor for clinical education has been recognized with multiple teaching awards. He was honored as the 2019 Physician Hero by the Philadelphia/Delaware Valley Crohn's and Colitis Foundation at their annual Take Steps for Crohn's & Colitis event, and wields digital and social media platforms to amplify education, outreach, and advocacy in IBD to clinicians and patients. He was also awarded the Philadelphia CCF's Chairman's Citation in 2022. He is the regular host of the academic podcast *GI Insights: IBD Crosstalk*, which features high-yield, evidence-based medicine discussions with guests from different interdisciplinary fields critical to providing comprehensive IBD care. Dr. Nandi's passions include fitness, cooking, virtual reality gaming, reading, and dancing. Follow him on social @fitwitmd.

# Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease



## Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

**Dr. Lichtenstein** reports the following financial relationships:

- Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly and Company (DSMB Data Safety Monitoring Board); Endo Pharmaceuticals; Ferring Pharmaceuticals; Gilead Sciences, Inc.; Janssen Orthobiotech (Funding to University of PA); Kabi Fresenius; MedEd Consultants, LLC; Merck & Co., Inc.; Morphic Therapeutic, Inc.; Pfizer Inc. (Funding to University of PA); Prometheus Laboratories, Inc.; Romark; Salix Pharmaceuticals/Valeant Pharmaceuticals; Sandoz; Shire Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc. (Funding to University of PA); UCB, Inc.; and Virgo Pharmaceuticals
- Research Support: Bristol Myers Squibb Company; Janssen Orthobiotech (Funding to University of PA); Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
- Other financial or material support: American Journal of Gastroenterology (Associate Editor); Gastro-Hep Communications (Editor); Professional Communications, Inc. (Royalty); SLACK, Inc. (Royalty); Springer Science and Business Media (Editor); and UpToDate – Walters Kluwer

**Dr. Nandi** reports the following financial relationships:

- Consultant: AbbVie Inc.; Boehringer-Ingelheim; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

The following individuals have no financial relationships to disclose:

- Rebecca Vargas-Jackson, MD (Peer Reviewer)
- Albert Eubanks, Jr., RN (Peer Reviewer)
- Mary Gleason, PhD (Planning Committee)
- John Jones, PharmD (Planning Committee)
- Kasey Brandt, PharmD (Planning Committee)
- Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
- Sandra Caballero, PharmD (Planning Committee)
- Sharon Tordoff (Planning Committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the U.S. Food and Drug Administration (FDA). The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

FORGING A NEW FRONTIER

# Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease



## Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

### 1. ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

### 2. VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

## Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



## Downloadable Resources

Downloadable resources will be available at:  
[www.cmeoutfitters.com/IBDresources](http://www.cmeoutfitters.com/IBDresources)

## Engage with Us

Follow us @[CMEOutfitters](https://twitter.com/CMEOutfitters) for announcements about upcoming CME opportunities, healthcare news, and more!

